Denali Therapeutics Inc. DNLI
20.39
(0.08)
(0.39%)
as of 25 Sep
- Market cap
- $3.4B
- P/E
- 0.0×
Follow DNLI
Growth Flags
show if company had growth for consecutive years
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | — | 0.00 | 0.00 | 0.00 | 214.77 | 0.00 | 0.00 | — | — |
P/S ratio |
— | — | 8.89 | 31.98 | 111.38 | 27.19 | 62.43 | 14.82 | — | — |
P/FCF ratio |
— | — | 0.00 | 0.00 | 0.00 | 22.10 | 0.00 | 40.96 | — | — |
P/Operating CF |
— | — | (29.78) | (47.73) | (82.76) | 17.76 | (34.96) | 20.54 | — | — |
P/B ratio |
— | — | 2.85 | 3.33 | 5.63 | 7.93 | 4.22 | 3.50 | — | — |
Price to Tangible BV |
— | — | 2.85 | 3.33 | 5.63 | 7.93 | 4.22 | 3.50 | — | — |
EV/Sales |
— | — | 5.90 | 20.15 | 94.81 | 23.01 | 49.45 | 11.22 | — | — |
EV/EBITDA |
— | — | 0.00 | 0.00 | 0.00 | 108.30 | 0.00 | 0.00 | — | — |
EV/Operating CF |
— | — | (5.45) | (8.93) | (21.83) | 18.56 | (8.70) | 28.92 | — | — |
EV/FCF |
— | — | (5.26) | (8.32) | (20.98) | 18.69 | (7.78) | 31.02 | — | — |
Quick Ratio |
8.82 | 8.14 | 13.27 | 3.67 | 2.29 | 20.50 | 9.16 | 14.16 | 28.68 | 19.58 |
Current Ratio |
9.16 | 8.46 | 13.65 | 3.77 | 2.37 | 20.86 | 9.48 | 14.67 | 28.92 | 19.98 |
Net Debt/EBITDA |
1.56 | 1.61 | 4.62 | 3.87 | 2.90 | (19.71) | 1.65 | 11.14 | 4.71 | 2.08 |
Debt/Assets |
0.48% | 0.41% | 0.00% | 3.63% | 4.20% | 3.99% | 12.47% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.01 | 0.00 | 0.00 | 0.05 | 0.06 | 0.06 | 0.17 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.25 | 0.08 | 0.03 | 0.31 | 0.04 | 0.22 | 0.00 | 0.00 |
Operating CF/Net income |
0.81 | 0.82 | 2.47 | 0.75 | 0.73 | 5.85 | 0.77 | (1.38) | 0.87 | 0.83 |
Capex/Depreciation |
(10.22) | 0.58 | 0.48 | (2.04) | (0.49) | (0.36) | (6.03) | (0.72) | (0.75) | (3.46) |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| (45.69%) | (37.40%) | (14.01%) | (32.52%) | (27.51%) | 9.21% | (41.97%) | (7.16%) | (47.46%) | 157.85% | |
| (40.69%) | (33.45%) | (11.11%) | (22.76%) | (19.32%) | 6.59% | (32.52%) | (6.31%) | (23.27%) | (56.31%) | |
ROIC |
(229.23%) | (75.59%) | 0.00% | 0.00% | (118.58%) | 0.00% | (274.53%) | (35.11%) | (94.57%) | (71.72%) |
Return on Tangible Assets |
(59.97%) | (51.72%) | (14.08%) | (30.97%) | (52.09%) | 4.86% | (45.81%) | (7.66%) | (21.49%) | (46.06%) |
Average Days of Receivables |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 128.24% | 330.74% | 545.31% | 63.34% | 724.87% | 110.86% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 31.27% | 83.42% | 162.47% | 17.97% | 174.23% | 25.05% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 32.71% | 92.06% | 175.19% | 15.00% | 143.86% | 14.55% | 0.00% | 0.00% |
Graham Net Nets |
— | — | 0.32 | 0.28 | 0.08 | 0.11 | 0.16 | 0.19 | — | — |
Graham Number |
— | — | 0.00 | 0.00 | 0.00 | 9.63 | 0.00 | 0.00 | — | — |
Earnings Yield |
— | — | (4.86%) | (9.41%) | (5.36%) | 0.47% | (11.83%) | (1.98%) | — | — |
Free Cash Flow Yield |
— | — | (12.62%) | (7.57%) | (4.06%) | 4.53% | (10.18%) | 2.44% | — | — |
Revenue per Share |
0.00 | 0.00 | 2.41 | 0.86 | 0.40 | 3.08 | 0.28 | 1.39 | 0.00 | 0.00 |
Operating CF per Share |
(2.39) | (2.11) | (2.61) | (1.95) | (1.74) | 3.82 | (1.59) | 0.54 | (5.12) | (11.19) |
Capex per Share |
(0.05) | (0.10) | (0.09) | (0.14) | (0.07) | (0.03) | (0.19) | (0.04) | (0.19) | (0.95) |
Free Cash Flow per Share |
(2.44) | (2.21) | (2.70) | (2.09) | (1.81) | 3.79 | (1.77) | 0.50 | (5.31) | (12.15) |
Cash per Share |
5.03 | 5.06 | 7.53 | 10.64 | 7.12 | 13.49 | 4.34 | 5.01 | 27.15 | 27.76 |
Shareholders Equity per Share |
5.87 | 7.48 | 7.50 | 8.30 | 7.92 | 10.56 | 4.13 | 5.90 | 31.13 | 39.61 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
5.87 | 7.48 | 7.50 | 8.30 | 7.92 | 10.56 | 4.13 | 5.90 | 31.13 | 39.61 |
Free Cash Flow |
(422.10) | (363.61) | (370.93) | (262.55) | (219.89) | 413.06 | (169.49) | 46.72 | (79.51) | (78.04) |
Working Capital |
802.31 | 762.23 | 986.16 | 1,008.40 | 518.99 | 1,423.96 | 384.69 | 448.05 | 395.44 | 172.85 |
Capital Expenditures |
(9.50) | (15.91) | (12.94) | (17.83) | (8.50) | (3.09) | (17.92) | (3.39) | (2.87) | (6.13) |
Net Current Asset Value |
769.57 | 719.94 | 941.17 | 954.51 | 455.36 | 1,041.91 | 271.69 | 365.70 | 388.68 | 165.41 |
EV/EBIT |
— | — | 0.00 | 0.00 | 0.00 | 123.12 | 0.00 | 0.00 | — | — |
Capex to Sales |
0.00 | 0.00 | 0.04 | 0.16 | 0.17 | 0.01 | 0.67 | 0.03 | 0.00 | 0.00 |
Net Profit Margin |
0.00% | 0.00% | (43.94%) | (300.56%) | (597.15%) | 21.19% | (740.74%) | (28.06%) | 0.00% | 0.00% |
Price to Operating Income |
— | — | 0.00 | 0.00 | 0.00 | 145.54 | 0.00 | 0.00 | — | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.02 | (0.49) | (0.60) | 0.20 | 0.45 | 0.21 | 0.06 | 0.19 | 0.26 | 0.12 |
Cash ROIC |
(24.64%) | (19.49%) | (19.54%) | (11.88%) | (13.26%) | 13.98% | (22.55%) | 2.47% | (10.50%) | (20.14%) |
Accounts Receivable Turnover |
— | — | 0.00 | 10.85 | 4.06 | 0.00 | 0.00 | 28.70 | 0.00 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | — | — | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | — | — | 0.00 | 0.00 | 0.00 |
Average Receivables |
— | — | — | 10.00 | 12.00 | — | — | 4.50 | 0.00 | 0.00 |
Average Payables |
7.23 | 10.31 | 6.14 | 3.78 | 2.93 | 1.83 | 2.24 | 2.30 | 2.34 | 1.84 |
Average Assets |
1,259.52 | 1,264.05 | 1,307.08 | 1,432.20 | 1,504.22 | 1,078.76 | 607.61 | 574.35 | 378.89 | 153.88 |
Average Common Equity |
1,121.72 | 1,130.32 | 1,036.69 | 1,002.36 | 1,056.41 | 772.71 | 470.87 | 506.32 | 185.82 | (54.89) |
Columns are period end dates